Savara (NASDAQ:SVRA) Shares Down 8.5% – Time to Sell?

Savara Inc (NASDAQ:SVRA)’s share price was down 8.5% during trading on Friday . The company traded as low as $2.83 and last traded at $2.92. Approximately 559,788 shares were traded during trading, a decline of 54% from the average daily volume of 1,209,018 shares. The stock had previously closed at $3.19.

Analyst Ratings Changes

A number of research firms recently issued reports on SVRA. HC Wainwright lowered their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Finally, Evercore ISI restated an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Stock Performance

The stock has a market capitalization of $502.85 million, a P/E ratio of -6.86 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.31 and a current ratio of 17.70. The company’s fifty day simple moving average is $3.91 and its two-hundred day simple moving average is $4.20.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). As a group, equities analysts forecast that Savara Inc will post -0.44 EPS for the current year.

Hedge Funds Weigh In On Savara

Hedge funds have recently added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC increased its position in shares of Savara by 2.3% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock worth $72,536,000 after purchasing an additional 332,706 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after buying an additional 4,157,385 shares during the period. Vestal Point Capital LP raised its position in shares of Savara by 24.7% in the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after buying an additional 1,600,000 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Savara by 17.5% during the 3rd quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock worth $28,547,000 after acquiring an additional 1,001,296 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after acquiring an additional 148,673 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.